25,729 articles
Bayer
Bayer AG, German life science company in Leverkusen with Pharmaceuticals, Consumer Health, and Crop Science divisions; founded 1863, maker of Aspirin, acquired Monsanto in 2018 for $63 billion, inheriting the Roundup glyphosate litigation.
Baylisascariasis
Baylisascariasis, also called raccoon roundworm infection, is human disease from Baylisascaris procyonis larvae ingested as eggs in raccoon-feces-contaminated soil, causing visceral, ocular, or severe neural larva migrans.
Baylor University Medical Center
Baylor University Medical Center (BUMC), Dallas, Texas; founded 1903 as Texas Baptist Memorial Sanitarium; flagship of Baylor Scott & White Health; 900+ beds, Level 1 trauma, CMS 4-star, Magnet hospital.
Bazedoxifene
Bazedoxifene (Conbriza, Duavee) is a third-generation SERM approved in the EU and Japan for postmenopausal osteoporosis, reducing vertebral fractures about 35-40% over 5 years; in the US it is sold only with conjugated estrogens.
Bazex syndrome
Bazex syndrome (acrokeratosis paraneoplastica) is a rare paraneoplastic dermatosis with acral psoriasiform lesions and nail dystrophy, usually preceding upper aerodigestive squamous cell carcinoma; distinct from Bazex-Dupré-Christol syndrome.
Bazex-Dupré-Christol syndrome
Bazex-Dupré-Christol syndrome (BDCS, follicular atrophoderma and basal cell carcinomas) is a rare X-linked dominant genodermatosis first described in 1964, causing hypotrichosis, milia, hypohidrosis, follicular atrophoderma, and early-onset basal cell carcinomas, mapped to Xq24-q27.1.
BB-1701 (HER2 ADC)
BB-1701 is an investigational anti-HER2 antibody-drug conjugate by BlissBio and Eisai, pairing a trastuzumab-sequence antibody with an eribulin payload (DAR 4) for HER2-positive and HER2-low solid tumors, including T-DXd-pretreated breast cancer.
BBIBP-CorV (Sinopharm Beijing inactivated COVID-19 vaccine)
The COVID-19 Vaccine (Vero Cell), Inactivated, known as BBIBP-CorV or the Sinopharm BIBP vaccine, is an inactivated COVID-19 vaccine developed in China and approved there in December 2020.
BC-1
BC-1 (CVCL_1079, ATCC CRL-2230) is a human B-cell line from a 1992 AIDS-related primary effusion lymphoma, dually infected with KSHV and EBV, used to culture KSHV and test lymphoma therapies.
BC-3
BC-3 (CVCL_1080) is a human primary effusion lymphoma B-cell line established in 1995 from an 85-year-old HIV-negative man's pleural effusion; it carries KSHV/HHV-8 without EBV, unlike earlier PEL lines.
BC-THAL study
BC-THAL study, formally Body Composition in Pediatric Patients With Thalassemia Major (NCT07204015), a ClinicalTrials.gov-registered study measuring fat mass and fat-free mass by bioelectrical impedance analysis in children with beta thalassemia major.
BCG Freeze Dried Glutamate vaccine
BCG Freeze Dried Glutamate vaccine: WHO-prequalified (since 1987) lyophilized tuberculosis vaccine from Japan BCG Laboratory's Tokyo 172 strain, stabilized with sodium glutamate, intradermal, 2-8°C, 24-month shelf life.
BCG therapy
BCG therapy is an intravesical immunotherapy for non-muscle-invasive bladder cancer in which a live weakened Mycobacterium bovis strain is instilled into the bladder after tumor resection, preventing recurrence in most patients.
BCG vaccine
BCG (Bacille Calmette-Guérin) is the only licensed tuberculosis vaccine, a live attenuated M. bovis vaccine from 1921 that protects infants against severe TB but shows variable (0-80%) protection against adult pulmonary TB.
BCG Vaccine AJV
BCG Vaccine AJV is a WHO-prequalified (since 1994) freeze-dried tuberculosis vaccine from AJ Vaccines A/S, Copenhagen, using live attenuated M. bovis BCG Danish strain 1331, given intradermally as a two-vial set with Sauton diluent.
BDD-G3S study
BDD-G3S (Database of Data Collection in Senological Surgery), NCT03461172, is an observational breast cancer surgery database run by Institut Paoli-Calmettes, Marseille, with over 25,000 records from more than 20 French centers, targeting 50,000 by 2026.
BE BRIGHT trial
BE BRIGHT (NCT03598790, PS0014) is UCB's completed multicenter open-label phase 3 extension trial of bimekizumab 320 mg in moderate-to-severe plaque psoriasis, following BE VIVID, BE READY, and BE SURE, with 3- and 4-year durability data.
BE COMPLETE trial
BE COMPLETE (NCT03896581) was a phase 3 trial of bimekizumab, a dual IL-17A/IL-17F inhibitor, in psoriatic arthritis patients with prior TNFα inhibitor failure; ACR50 43% vs 7% placebo at week 16.
BE MOBILE 1 trial
BE MOBILE 1 (NCT03928704) is UCB's phase 3, double-blind, placebo-controlled trial of bimekizumab 160 mg every 4 weeks in active nonradiographic axial spondyloarthritis, run in parallel with BE MOBILE 2; ASAS40 primary endpoint met at week 16 and sustained to week 52.
BE MOBILE 2 trial
BE MOBILE 2 (NCT03928743) is the pivotal phase 3 trial of bimekizumab 160 mg every 4 weeks in active ankylosing spondylitis; 332 patients, ASAS40 45% versus 23% placebo at week 16, sustained to week 52.
BE OPTIMAL trial
BE OPTIMAL (NCT03895203) is a 52-week phase 3 trial of bimekizumab (Bimzelx), a dual IL-17A/IL-17F inhibitor, in 852 biologic-naive psoriatic arthritis patients; ACR50 at week 16 was 44% vs 10% placebo.
BE RADIANT trial
BE RADIANT (NCT03536884, PS0015) was UCB Pharma's phase 3b trial comparing bimekizumab, a dual IL-17A/IL-17F inhibitor, with secukinumab, an IL-17A inhibitor, in 743 plaque psoriasis patients; bimekizumab cleared skin better but caused more oral candidiasis.
BE VITAL trial
BE VITAL (NCT04009499) is UCB's phase 3 open-label extension trial of bimekizumab 160 mg every 4 weeks in psoriatic arthritis, enrolling 1,131 completers of BE OPTIMAL and BE COMPLETE for long-term safety and efficacy follow-up.
BE VIVID trial
BE VIVID (NCT03370133) was a 52-week phase 3 trial comparing bimekizumab, a dual IL-17A/IL-17F inhibitor, with ustekinumab and placebo in plaque psoriasis; 85% achieved PASI90 at week 16 versus 50% and 5%.
BE_WITH trial
BE_WITH (NCT07204444), the BE WITH Project, a completed University of Florida partially nested randomized trial testing 8-week warm calls (BE and BE+ASIST conditions) for loneliness, depression, and suicide risk in 671 older adults.
BE-13
BE-13 (CVCL_1081, RRID:CVCL_1081) is a human T-cell leukemia cell line first described in 1981 from a T-ALL patient; it is a documented derivative (tetraploid subclone) of the PEER line, ICLAC-00178, DSMZ ACC-396, with NUP214-ABL1, NOTCH1 L1600P, and TP53 Y163C.
Beard
Beard: androgen-driven terminal facial hair of men, grown from puberty. Covers biology, minoxidil beard trials, pseudofolliculitis barbae, bacterial colonization and shedding evidence in surgeons, and beard history.
Bearded lady
Bearded lady: a woman with visible male-pattern facial hair, known from 1840-1914 sideshows and Julia Pastrana; medically hirsutism, caused by PCOS in 80-90% of cases, measured by the mFG score.
BeatPark trial
BeatPark trial: Montpellier clinical trials (NCT02438124, NCT02647242, NCT04543058) of BeatPark, a wearable device delivering music synchronized in real time to gait cadence via ankle sensors for gait rehabilitation in Parkinson's disease.
Beau's lines
Beau's lines, also called transverse nail grooves, are horizontal dents in fingernails or toenails caused by temporary arrest of the nail matrix after illness, chemotherapy, trauma, or infection; they grow out in about six months.